Overview of Mapesil

Mapesil is a synthetic, fixed-dose combination product specifically classified as an upper respiratory combination.

Property	Description
Active Ingredient	Chlorphenamine maleate, Phenylpropanolamine hydrochloride
Form	Oral tablet, oral liquid, oral suspension
Pharmacological Class	Upper Respiratory Combination
General Purpose	Symptomatic relief of cold and allergy symptoms
Origin	Synthetic

What Type of Medicine is Mapesil and What is Its Purpose?

Mapesil is a synthetic, fixed-dose combination product classified within the pharmaceutical field as an upper respiratory combination. Its fundamental purpose is to provide symptomatic relief from the collective discomforts associated with upper respiratory issues, which include the common cold and various forms of allergic rhinitis. This product is defined by its integrated pharmacological approach, containing two active components that target distinct symptom pathways, a strategy clinically recognized for the comprehensive management of these conditions.

This dual-component design distinguishes Mapesil from single-agent antihistamines, offering an accessible, Over-the-Counter (OTC) approach to managing multiple symptoms simultaneously, such as sneezing, rhinorrhea (runny nose), and nasal blockage.

Composition and Form: The Active Ingredients

Mapesil contains two primary synthetic active substances: Chlorphenamine maleate and Phenylpropanolamine hydrochloride. Chlorphenamine maleate is a first-generation antihistamine, chemically derived from the alkylamine class, which works as a histamine H1 receptor antagonist. Phenylpropanolamine hydrochloride is a sympathomimetic agent that serves as the nasal decongestant component. Mapesil is prepared for oral administration and is typically manufactured as an oral tablet, or alternatively as an oral liquid or oral suspension, often engineered for prolonged symptomatic management.

General Benefit: How the Dual-Action System Provides Relief

The general benefit of Mapesil is derived from its two complementary actions, which address the primary discomforts of respiratory conditions. The antihistamine component reduces the effects of histamine, which helps to alleviate classic allergy symptoms. Concurrently, the decongestant component acts to induce vascular constriction in the nasal mucosa, reducing tissue hyperemia and swelling. This vasoconstrictive action is supported by pharmacological studies for its role in reducing nasal airway resistance. This combined mechanism is designed to ease nasal congestion and the sensation of pressure that often accompanies upper respiratory irritation.

What side effects are possible with Mapesil?

Possible Side Effects and Safety Information

Regulatory documents classify the potential effects of Mapesil (Chlorphenamine maleate and Phenylpropanolamine hydrochloride) by frequency and the body system affected. These classifications formally define the product's safety profile.

Adverse Reaction Scope

The most commonly listed adverse reactions are often associated with the antihistamine component. The official classifications include:

Classification	Examples of Reactions (System Organ Class)
Very Common	Sedation, Somnolence (Drowsiness) (Nervous System)
Common	Disturbance in attention, Dizziness, Headache, Dry mouth, Nausea, Fatigue (Multiple Systems)
Uncommon/Unknown	Vomiting, Abdominal pain, Urinary retention, Excitation, Restlessness (Multiple Systems)

Serious adverse reactions, though typically reported as rare or very rare, are explicitly documented in regulatory sources and affect multiple systems. These include Hemorrhagic Stroke (risk associated with the Phenylpropanolamine component), severe Hypertension, Tachycardia, and various Blood Dyscrasias (e.g., Agranulocytosis, Aplastic Anaemia). Anaphylactic reactions and Convulsions (Seizures) are also listed as serious potential adverse effects.

Safety-Related Constraints and Populations

Official safety statements note specific populations and pre-existing conditions that require caution. Both children and the elderly are noted as being more susceptible to certain neurological effects and paradoxical reactions, such as increased restlessness and confusion. Caution is also specified for individuals with severe hepatic or severe renal impairment.

Furthermore, the label advises caution when the product is administered to individuals with specific pre-existing conditions, including Severe Hypertension, certain Cardiovascular diseases, Epilepsy, Glaucoma (raised intra-ocular pressure), and Thyrotoxicosis. The use of Mapesil with alcohol or other CNS depressants is documented to potentially cause an increase in sedative effects.

Overdose and Emergency Response

Mapesil overdose has the potential to cause serious harm and requires immediate emergency medical attention regardless of the presence or severity of initial symptoms. Official regulatory documents stress the need to contact emergency services or a Poison Help line immediately upon suspected overdose.

Overdose manifestations are primarily characterized by severe effects on the Central Nervous System (CNS) and the cardiovascular system, derived from the active components. CNS presentations may include a spectrum ranging from profound drowsiness, sedation, and coma to paradoxical excitation, agitation, hallucinations, and toxic psychosis. Additionally, anticholinergic signs such as dry mouth, mydriasis (dilated pupils), and urinary retention are officially documented.

Life-threatening outcomes explicitly listed in regulatory labeling include severe hypertension, cardiac arrhythmias, cardiovascular collapse, seizures (convulsions), stroke (intracranial hemorrhage), and respiratory failure.

The official management approach is strictly supportive and symptomatic, as no specific antidote is available. Management requires rigorous observation, which includes continuous monitoring of vital signs and cardiac function (ECG) in a hospital setting. Furthermore, official labeling notes that children and the elderly may be more susceptible to neurological effects, particularly paradoxical excitation, following an overdose.

Therapeutic Uses of Mapesil

Mapesil is commonly used to provide short-term symptomatic assistance in situations involving certain distressing symptoms of the upper respiratory tract. The product is applicable within clinical settings that involve acute or disruptive symptom patterns, and is commonly used to help with conditions such as allergic rhinitis, vasomotor rhinitis, and the common cold. This combination may assist with easing the overall symptom load.

Therapeutic Scope and Key Benefits

This combination is applied across domains where additional symptomatic support is needed to address groups of symptoms that interfere with daily functioning, including frequent sneezing, watery eyes, rhinorrhea (runny nose), and physical nasal congestion. The product is commonly used across conditions presenting with acute episodes where multiple symptoms occur together.

“Mapesil contributes to improved comfort during periods of heightened symptoms and supports the patient during difficult episodes by easing the physical sensation of blockage.”

It is relevant when symptoms become temporarily overwhelming, offering support that helps ease the overall symptom burden associated with both allergic flares and the acute phases of a cold.

Quick Fact: Relief for Dual Symptoms
Primary Focus: Alleviating the simultaneous discomfort of both nasal secretions and nasal swelling that accompany colds and allergies.

Regulatory References

Philippine FDA Verification Portal

Eligibility and Restrictions for Use

The eligibility for using Mapesil, which contains Chlorphenamine and Phenylpropanolamine, is strictly defined by regulatory authorities based on age, pre-existing conditions, and physiological status.

Populations for Whom Use is Contraindicated

The medicine must not be used by individuals with certain pre-existing medical conditions due to the risk of serious complications, as stated in official labeling. This includes patients with:

High Blood Pressure (Hypertension) or any type of Heart Disease or Heart Rate Irregularity.
Toxic Goiter (Hyperthyroidism) or Glaucoma.
Lower Respiratory Tract Disease.
Brain Damage or Epilepsy.
Absolute Prohibition: Patients currently taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping them.

Age and Condition-Related Restrictions

Eligibility Status	Applicable Population	Specific Regulatory Constraint
Use Not Recommended	Children Under 6 Years Old	Not typically recommended for the oral tablet formulation.
Conditional Use	Older Adults (Geriatric)	Use requires caution due to increased susceptibility to neurological effects, such as confusion.
Conditional Use	Hepatic or Renal Impairment	Use is restricted and requires medical guidance due to altered drug metabolism and excretion.
Not Recommended	Breastfeeding Individuals	Use is not recommended, and is often prohibited, as the components may pass into breast milk.

Regional Eligibility Note

The Phenylpropanolamine component has been identified by the U.S. FDA as not generally recognized as safe and effective (Category II) and was requested to be withdrawn from the market due to the risk of hemorrhagic stroke, constituting a major non-eligibility status in that region.

What should I know about interactions with other medicines?

Mapesil Interactions with other medicines and products

The interaction profile for Mapesil, a combination product containing Chlorphenamine maleate and Phenylpropanolamine hydrochloride, is defined by constraints documented in official government regulatory information.

Interaction Type	Interacting Medicines and Products	Official Regulatory Description
Contraindicated Combination	Monoamine Oxidase Inhibitors (MAOIs) (e.g., Phenelzine, Tranylcypromine)	Co-administration is formally prohibited during treatment or within 14 days of stopping MAOI therapy. This restriction addresses the potential for a dangerous drug interaction, including hypertensive crisis.
Pharmacodynamic Enhancement	Alcohol, CNS Depressants (e.g., Hypnotics, Tranquilizers), Anticholinergic Drugs	May result in additive CNS depression (e.g., increased drowsiness) or enhanced anticholinergic effects (e.g., dry mouth) [Additive effects].
Cardiovascular/Pressor Risk	Tricyclic Antidepressants (e.g., Amitriptyline), Antihypertensive Medications	May potentiate the pressor effect of Phenylpropanolamine or decrease the antihypertensive activities of medicines like Methyldopa and Beta Blockers [Decreased drug efficacy].
Metabolic Interference	Phenytoin ( Anti-epilepsy medicine)	Chlorphenamine is reported to inhibit metabolism which can increase the plasma levels of Phenytoin.

Connection to the overall interaction profile

The regulatory documents establish a structured interaction profile emphasizing a formal prohibition with MAOIs and caution regarding additive depressant effects with alcohol and CNS depressants. This is further defined by warnings concerning cardiovascular risk potentiation and the clearance interference that may increase the exposure of Phenytoin. The profile focuses on the specific risks associated with the dual pharmacological classes present in the product.

Mechanism of Action

Mapesil functions as a nitrogen-containing bisphosphonate that achieves targeted, selective accumulation on the bone surface. Its bisphosphonate moiety binds directly to hydroxyapatite crystals, which are exposed in areas of active bone remodeling and high osteoclast activity. Once internalized by the active osteoclast during the process of resorption, Mapesil inhibits the critical enzyme farnesyl pyrophosphate synthase (FPPS) within the cell. This inhibition prevents the formation of key isoprenoid lipids, such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). The depletion of these lipids prevents the necessary post-translational prenylation of small GTPase proteins (like Rho, Rac, and Rab), which are essential for maintaining the osteoclast cytoskeleton, vesicular trafficking, and ruffled border integrity. The downstream cascade leads to the progressive disruption of the cell's internal architecture and signaling capabilities, ultimately inducing osteoclast apoptosis (programmed cell death). The resulting physiological modulation is a reduction in the number and functional activity of osteoclasts, leading to a measured decrease in the overall rate of bone resorption.

Dosage and Administration Information

How Mapesil is Used: Official Administration Guidelines

The administration of Mapesil (Chlorphenamine Maleate / Phenylpropanolamine HCl) follows specific instructions outlined in prescribing information for approved combination products.

Official Route and Forms

Mapesil is approved for the oral route of administration. The medication is manufactured as an oral tablet, oral liquid, or oral suspension.

Standard Dosing and Frequency

The product is intended for short-term symptomatic relief. For adults and children aged 12 years and over, the standard immediate-release dose (e.g., 2 mg / 12.5 mg) is typically 1 tablet taken every 4 to 6 hours as needed. It is critical not to exceed the maximum recommended dose of 6 standard doses in a 24-hour period. Treatment duration should generally not exceed 7 days without consulting a healthcare professional.

Procedural and Population Rules

Administration Aspect	Official Instruction
Preparation	Liquid forms must be measured with a calibrated dosing device.
Ingestion	Tablets should be swallowed whole; extended-release forms must not be crushed or chewed.
Food Context	May be taken with or without food.
Older Adults (ge 65)	A lower dose may be required due to increased sensitivity.
Children (6–12 years)	Dosing is lower than the adult dose, often every 6 hours, following specific pediatric guidelines.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mapesil

Evidence for Use in Common Cold Symptomatic Relief

Research evidence for this combination product was explored primarily through short-term Randomized Controlled Trials (RCTs) and related Systematic Reviews that synthesize data from these trials. This research was studied for its use in exploring how symptoms change over time during the acute phase of the common cold. Studies have mainly measured changes in Total Symptom Scores (TSS), which reflect the overall burden of symptoms like runny nose, sneezing, and nasal blockage, as well as patient-reported outcomes describing perceived discomfort.

Research has explored whether the combination has an association with the overall episodic or acute symptom patterns in adults and older children. Findings describe patterns observed in the studies related to a temporary change in global symptoms when compared to placebo. However, evidence is noted as limited and mixed when looking at the measured change in some individual cold symptoms alone.

Evidence for Use in Allergic Rhinitis Symptomatic Relief

The combination was studied for allergic rhinitis in settings involving fluctuating or episodic symptom patterns. Randomized Controlled Trials were conducted to evaluate the product's profile in the context of symptoms associated with upper respiratory allergies, primarily in adults and adolescents. Research examined outcomes related to physical discomfort, specifically measuring changes in Total Nasal Symptom Scores and specific assessment of nasal congestion. Studies report how symptoms evolved in the observed populations across defined time intervals, with follow-up typically up to a few weeks.

Study Duration and Research Limitations

The majority of clinical research involving this combination product is structured around short-term study protocols. The evidence base therefore provides limited information for long-term outcomes, as the studies are designed to assess acute relief over periods such as three to ten days. Furthermore, the largest body of evidence applies to adults, while data for certain groups, such as young children (e.g., those le 5 years), remain insufficient or mixed. A noted research challenge is the difficulty in separating the contribution of each active component within the single-product study design.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Mapesil (FAQ)

Q: Is Mapesil available over-the-counter or does it require a prescription?

According to official drug classifications, Mapesil, or products containing its combination of active ingredients, is described as a nonprescription medicine, often referred to as Over-the-Counter (OTC). This classification is based on regulatory status in regions where it is approved for sale.

Q: What happens if I miss taking Mapesil?

Regulatory information describes how to handle a missed dose for medicines of this type. It is generally described that the missed dose should be used as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is to be skipped entirely, and the regular schedule should be resumed. Regulatory guidance describes that a double dose should not be used to make up for a missed dose.

Q: Is there a generic version of Mapesil available?

Yes, the combination product containing Chlorphenamine maleate and Phenylpropanolamine hydrochloride is available from various manufacturers. In regions where it is approved, it is typically sold under multiple brand names as well as generic, non-branded forms.

Q: Can Mapesil be used by children?

Regulatory documents state that Mapesil is typically not recommended for children under 6 years old. For children in the 6 to 12 age range, official guidelines specify that a lower dosage must be followed. The complete restrictions on who can and cannot use the medicine are outlined in the official regulatory documents.

Q: Why are people often confused about the proper timing for Mapesil use?

The recommended dosing frequency of every 4 to 6 hours is described in regulatory prescribing information to align with the estimated duration of symptomatic relief. This period is based on how long the drug's components are expected to act in the body.

Q: Does taking Mapesil require monitoring by a healthcare provider?

Official warnings advise caution for use in individuals with certain pre-existing conditions, such as severe high blood pressure (hypertension), glaucoma, or severe hepatic (liver) or renal (kidney) impairment. These warnings indicate that professional guidance is needed for using the product in these populations.

Q: Is Mapesil known to cause weight changes?

Weight change is not consistently listed as one of the most common or very common adverse reactions in the official regulatory profiles for the Mapesil combination product. The official information focuses on frequently reported effects, such as drowsiness, dry mouth, and dizziness.

Q: What should I know about taking Mapesil with common pain relievers?

Official regulatory documents define specific contraindications and interactions with drug classes like MAOIs, CNS depressants, and certain heart medications. Common Over-the-Counter pain relievers, such as acetaminophen or ibuprofen, are generally not listed as having formal, major contraindications with the components of Mapesil.

Q: Is Mapesil the same type of medicine as [similar drug name]?

Mapesil is a specific fixed-dose combination of two types of medicine: a first-generation antihistamine (Chlorphenamine maleate) and a sympathomimetic decongestant (Phenylpropanolamine hydrochloride). This combination places it specifically in the pharmaceutical class of an Upper Respiratory Combination product.

Q: How quickly does Mapesil usually start working?

Regulatory pharmacokinetic information describes how quickly the ingredients are absorbed. Peak concentration levels for the decongestant component are generally observed around 1 to 2 hours after administration, while the peak for the antihistamine component typically occurs between 2.5 to 6 hours.

Q: How long does the effect of one use of Mapesil usually last?

The reported duration of symptomatic relief for one standard dose is typically described in regulatory information as being between 4 to 6 hours. This expected duration of effect aligns with the product's recommended dosing interval.

Q: What is the legal classification or schedule of Mapesil in my country?

Mapesil is described in general regulatory records as a nonprescription drug (OTC). Furthermore, in systems that use controlled substance classification, the product typically holds a 'No Control' status.

Q: Why do some sources say Mapesil is for [Condition A] and others say [Condition B]?

Official regulatory documents clearly describe Mapesil's approved purpose as the symptomatic relief of discomforts associated with the common cold and allergic rhinitis. Regulatory documents do not describe use for any purposes outside of these officially approved indications.

Q: How does Mapesil compare structurally to older medicines for the same purpose?

The antihistamine component, Chlorphenamine maleate, is structurally classified as a first-generation antihistamine. This classification indicates that this specific component belongs to one of the older pharmacological classes used for symptomatic relief of allergies and cold symptoms.

Q: What is the half-life of Mapesil?

The half-life of the two components differs substantially. The half-life for the decongestant component, Phenylpropanolamine, is reported to be about 3 to 5 hours. The half-life for the antihistamine component, Chlorphenamine, is described as having wide variation between individuals, with reported values ranging from 2 to 43 hours.

Q: What kind of studies were used to approve Mapesil?

Research evidence used to support the approved uses of Mapesil was primarily collected from short-term Randomized Controlled Trials (RCTs). These studies were designed to measure the acute change in common cold and allergic rhinitis symptoms over short, defined time periods.

Q: Is it possible for Mapesil to lose its effectiveness over time?

Regulatory documents note that tolerance to the therapeutic effects of the decongestant component, Phenylpropanolamine, has been reported with prolonged or extended use of the medicine. This indicates that a diminished effect may occur with continuous use.

Q: Are there different strengths or formulations of Mapesil available?

Mapesil is manufactured in various physical forms, including an oral tablet, oral liquid, and oral suspension. These forms are available in different dosage strengths defined by the manufacturer and relevant regulatory authorities.

Q: What is the chemical name of the active ingredient in Mapesil?

The active ingredients have complex, formal chemical designations used in scientific and regulatory contexts. The formal chemical description for the combination involves naming the constituents: (1S,2R)-2-amino-1-phenylpropan-1-ol;(E)-but-2-enedioic acid;3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine;hydrochloride.

Q: What is the typical timeframe for seeing the full benefits of Mapesil?

Mapesil is indicated for short-term symptomatic relief rather than long-term condition management. Research evidence is based primarily on studies assessing acute change in symptoms over short periods, such as three to ten days. The research is structured to assess how symptoms change over these defined, acute periods.

Q: Why is Mapesil described as a 'new generation' medicine?

Official classification places the antihistamine component, Chlorphenamine maleate, within the older group of first-generation antihistamines. The overall product is a combination, and it is not typically described in official documents as a 'new generation' medicine.

Q: What is the difference between the main ingredient and the inactive ingredients in Mapesil?

The active ingredients (Chlorphenamine and Phenylpropanolamine) are the components described in regulatory documents as addressing the symptoms. Inactive ingredients are all other substances included in the formulation, such as colorants or binders, that have no intended therapeutic effect.

How should Mapesil be stored and disposed of?

Official Storage and Disposal Instructions

The medicine Mapesil, an upper respiratory combination, must be stored and handled according to specific regulatory requirements to ensure its stability and integrity.

Requirement	Official Statement/Condition
Storage Temperature	Store the product at Controlled Room Temperature (CRT), maintaining a range of 20 C to 25 C (for tablets). Liquids must not exceed 30 C.
Handling/Protection	Protect from moisture and excessive heat. Liquid and suspension forms must not be frozen as this may affect the product’s physical stability.
Container Rules	Keep the medicine in its original container and ensure the container is tightly closed when not in use.
Child Safety	It is required that the product be stored out of the sight and reach of children.

Disposal of Unused Product: Any unused or expired Mapesil must not be thrown away via household waste or wastewater. Disposal should be carried out in accordance with local requirements established for unused or expired medicines.

Mapesil